Kestra Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Kestra Advisory Services’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$44.9K	Sell	10,880 -1,198	-10%	-$4.06K	﹤0.01%	3398
2026 Q2	$44.3K	Sell	12,078 -4,921	-29%	-$16.4K	﹤0.01%	3218
2026 Q1	$52.2K	Sell	16,999 -13,152	-44%	-$50.8K	﹤0.01%	3058
2025 Q4	$123K	Sell	30,151 -2,666	-8%	-$13.2K	﹤0.01%	3260
2025 Q3	$160K	Sell	32,817 -348	-1%	-$1.83K	﹤0.01%	2775
2025 Q2	$168K	Sell	33,165 -9,990	-23%	-$49.1K	﹤0.01%	2680
2025 Q1	$228K	Buy	43,155 +15,153	+54%	+$110K	﹤0.01%	2385
2024 Q4	$189K	Buy	+28,002	New	+$188K	﹤0.01%	2500

Other funds holding RXRX

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Allen Operations New York $968M AUM 12.84% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Kestra Advisory Services's RXRX Position: Q3 2026 in Review

Kestra Advisory Services reduced its Recursion Pharmaceuticals (RXRX) stake by 9.9% in Q3 2026, selling an estimated $4.06K and leaving 10,880 shares worth $44.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3398.

Kestra Advisory Services first reported a position in RXRX in Q4 2024 and has held it in 8 quarters since. The position peaked at $228K in Q1 2025. 111 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Kestra Advisory Services held 10,880 shares of Recursion Pharmaceuticals worth $44.9K as of Q3 2026.
Kestra Advisory Services sold 1,198 Recursion Pharmaceuticals shares in Q3 2026, an estimated $4.06K.
Recursion Pharmaceuticals made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #3398 holding.
Kestra Advisory Services first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
Kestra Advisory Services's Recursion Pharmaceuticals position peaked at $228K in Q1 2025.
111 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.